Polyram 2025: Growth Without Backlog, and Who Funds the Inventory
Polyram’s 2025 expansion was built on a broad customer base and recurring orders, but not on firm backlog. Inventory stayed heavy, operating working capital rose, and the balance sheet kept funding the gap until the new capacity fills up.
What This Follow-up Is Isolating
The main article established the wider point: Polyram is building a broader global footprint, but 2025 was still a test year for margins and funding structure. This follow-up isolates one layer of that story: demand quality. Not whether customers exist, but whether the company has enough contractual visibility to justify the new capacity and the inventory it is already carrying.
Three points matter before anything else:
- Polyram does not have a customer-diversification problem. It has about 1,100 customers, no customer accounts for 10% of revenue, and in the company presentation the top 20 customers together account for only 34% of sales.
- Polyram does have a visibility problem. Across all three divisions, management does not run the business through backlog, and in engineering compounds it explicitly says there are no long-term contracts. Forecasts exist, but they are not a substitute for firm orders.
- That is why the balance sheet matters. Inventory remained high, operating working capital rose from NIS 413.1 million to NIS 440.8 million, and the incremental funding burden was taken mainly through short-term bank debt, which climbed to NIS 273.5 million.
What is working today is the commercial model: direct sales to about 88% of end customers, a wide geographic footprint, fast delivery capability, and a credit-insurance framework that covers more than 98% of receivables, excluding LAPO at the end of 2025. The yellow flag is elsewhere. Growth is moving faster than contractual certainty. This is not a story of backlog waiting to be recognized. It is a story of plants, lines, and inventory being built before demand is contractually locked in.
No Backlog, Only Forecasts, Inventory, and Fast Delivery
Polyram is explicit about this. In engineering compounds there are no long-term contracts, lead time is roughly two weeks to one month, and some customers provide annual purchase forecasts that are updated quarterly. At the same time, the company manufactures for stock even without a specific order, based on past experience and purchase forecasts. In Bondyram the language is even sharper: these are shelf products, with no fixed commercial agreements, and no backlog there either. In Polytron there are framework orders with automotive customers, but even there management writes that it does not treat undelivered orders as an effective management tool, so in its own framing there is no backlog here as well.
That does not mean demand is weak. Quite the opposite. Customer diversification is strong, there is no dependence on a single customer, and a large part of the product portfolio is consumed on a recurring basis. But that is commercial repeatability, not contractual visibility. If activity slows, the company does not lean on a signed order book. It leans on delivery speed, inventory availability, and competitive pricing.
| Segment | What exists instead of backlog | What management says about customers | Average utilization |
|---|---|---|---|
| Engineering thermoplastic compounds | Annual forecasts updated quarterly, production for stock, short lead-time orders | No long-term contracts, no customer dependence | 62% |
| Bondyram | Shelf products and stock-building for recurring customers | No fixed agreements, no customer dependence | 52% |
| Polytron | Framework orders in automotive, but not treated as managerial backlog | No customer dependence, global automotive exposure | 54% |
That is the key datapoint. An industrial company can add capacity before demand fully arrives, but then the question becomes who carries the transition period. At Polyram, the answer is not backlog.
The Capacity Is Already Here, the Load Factor Is Not
2025 was a clear capacity-expansion year. In Thailand the company built a Bondyram site with roughly a USD 6 million investment, production started at the beginning of the fourth quarter of 2025, and the first phase included two production lines. The company already ordered an additional line for the site, expected to start operating in the second half of 2026. In the US, the board approved in March 2025 an additional engineering-compounds line with an expected cost of roughly USD 1.5 million. At the same time, the LAPO acquisition in November 2025 added production capability in Italy and Morocco, and the presentation translates that into roughly 33 thousand tons of added capacity.
The issue is not the investment itself. The issue is the economic timing. In the presentation, the company frames maximum production capacity at 151.9 thousand tons across the territories, excluding LAPO, with current utilization of about 65%. The annual report tells a similar story from a more granular angle: 62% in engineering compounds, 52% in Bondyram, and 54% in Polytron. In plain language, Polyram is building the next leg of growth while the existing system is still far from fully loaded.
That is not automatically negative. Sometimes this is exactly how a company captures demand before competitors do. But growth without backlog, alongside utilization in the mid-50s to low-60s, is a much more balance-sheet-dependent growth story than a standard industrial expansion case. The company pays upfront for capacity, sites, logistics, and inventory in order to guarantee service and availability. The reward only comes later, if utilization closes the gap.
Who Funds the Inventory
At first glance, inventory barely moved: NIS 337.0 million at the end of 2025 versus NIS 338.6 million at the end of 2024. But that is exactly the point. Polyram is not entering 2026 with a temporarily bloated inventory position. It is entering with a structurally heavy inventory platform. Inventory days rose to 85 in 2025, after 83 in 2024 and 69 in 2023. The balance-sheet breakdown also shows raw and auxiliary materials rising to NIS 163.1 million while finished goods fell to NIS 173.9 million. In other words, the company is not only carrying finished goods for fast service, it is also expanding the raw-material layer in order to stay ready for demand.
That burden becomes clearer once receivables and suppliers are added. Receivables rose to NIS 176.6 million, while payables to suppliers fell to NIS 72.8 million from NIS 99.3 million a year earlier. The economic meaning is straightforward: the company received less operating funding from suppliers in the same year in which it maintained high inventory and kept extending customer credit.
The bridge is simple: receivables plus inventory, less suppliers, created net operating working capital of NIS 440.8 million, versus NIS 413.1 million a year earlier. The NIS 27.6 million increase did not come from an inventory spike alone. It came from a combination of three things: inventory staying heavy, receivables edging higher, and suppliers dropping sharply. In other words, part of the funding burden shifted away from suppliers and onto Polyram’s own balance sheet.
The credit terms tell the same story. In Israel, the company extends credit of up to current plus 60 to 120 days, with an average credit period of 102 days in 2025. Outside Israel, it extends credit of up to current plus 30 to 90 days, and the average period increased to 51 days from 44 days in 2024. Most sales are insured, and about 98% of the credit extended to Israeli customers is covered by credit insurance, but that reduces loss risk, not the need to fund the receivable days themselves. LAPO is even less complete at this stage: at the end of 2025 there were customer-credit procedures in place, but still no credit insurance, and the company says it is working to implement the group insurance policy there as well.
This is the part the market can miss. Credit insurance lowers credit risk. It does not create cash. If the commercial model relies on inventory availability, fast delivery, and customer credit, someone still has to finance all three.
Who Funds the Capacity
Here the balance sheet moves to center stage. Short-term bank debt and other short-term credit rose to NIS 273.5 million at the end of 2025, versus NIS 215.9 million a year earlier. Total bank debt, short and long term, reached NIS 314.5 million. Against that, cash stood at just NIS 38.3 million. That leaves net bank debt of roughly NIS 276.2 million.
That debt is not only about LAPO. Even before the acquisition itself, 2025 was a year in which the company rolled out new capacity, expanded the US site, opened Thailand, and carried a heavy working-capital base. The company also notes that 86% of its funding sources are tied to floating rates based on prime, SOFR, or ESTR. That means the time gap between investing in capacity and filling capacity is not just a waiting period. It is also an interest-bearing period.
There is no covenant stress here today. Net debt to EBITDA must remain below 4, and the actual ratio at the end of 2025 was about 2.09. That is a comfortable margin. So this is not a near-term balance-sheet edge case. It is a question of economic quality. When demand is not locked in via backlog, and utilization is still middling, every new capacity step temporarily increases dependence on short-term bank funding and floating-rate debt.
The Cash Bridge: The Business Generates Cash, but Not Enough for All Uses
To avoid mixing operating cash generation with financing flexibility, two pictures need to be separated here. At the operating level, the company generated NIS 100.5 million of cash flow from operations in 2025. That is not a small number, and it shows that the core business still produces cash.
But the all-in picture looks different once the year’s actual cash uses are included. The company invested NIS 60.9 million in fixed assets and other property, paid NIS 45.1 million net for the LAPO acquisition, distributed NIS 30.0 million in dividends, repaid NIS 13.7 million of lease principal, and repaid NIS 18.4 million of long-term bank debt. That creates a shortfall of roughly NIS 67.6 million before any increase in short-term borrowing. Even if LAPO is stripped out as a one-off strategic move, there is still a gap of roughly NIS 22.6 million after reported CAPEX, dividends, lease principal, and long-term debt repayment.
That leads to the direct answer in this follow-up. Inventory and capacity were not funded by customers, not by suppliers, and not by operating cash flow alone. They were funded mainly by bank lines and by the balance sheet. That stands out even more because supplier payables actually fell in the same year, meaning the company did not pass the burden down the chain.
What Needs to Be Proven From Here
The counter-thesis is clear and intelligent. This may be exactly the right price to pay in a bridge year. Polyram operates in markets where delivery speed, product customization, and geographic reach are real competitive moats. If Thailand, the additional US line, and LAPO fill up, utilization will rise and the balance sheet will look materially lighter a year from now. In that case, 2025 will look in hindsight like a build-out year, not like a sign of weak demand quality.
But that is still not the conclusion the evidence supports at year-end 2025. What the evidence does support is that the company is making a calculated balance-sheet bet. It is building capacity before backlog exists, carrying inventory in order to guarantee service, extending customer credit to preserve commercial continuity, and funding the transition mostly with short-term bank debt. As long as utilization stays in the 52% to 62% range and operating working capital keeps climbing, this remains a financing-first story before it becomes an operating-leverage story.
The real checkpoint in the coming reports is straightforward: not whether Polyram keeps talking about growth, but whether the new sites start returning cash. If that happens, 2025 will register as a bridge year. If it does not, the issue will turn out not to be demand on paper, but the balance-sheet price the company is paying to keep that demand alive.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.